|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Survival in women with recurrent or metastatic cervical cancer remains poor. More effective and less toxic regimens are needed. Cisplatin is an effective radiosensitizer, but its single agent activity in recurrent cervical cancer, especially after prior cisplatin exposure, is disappointing, with a response rate of only 13%. Oxaliplatin has preclinical activity in cisplatin-resistant tumors and may have synergic activity when combined with paclitaxel. Our objective is to determine the efficacy and toxicity of paclitaxel and oxaliplatin in patients with recurrent or metastatic cervical cancer.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-10202165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-10572615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-11085200,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-11762817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-12960739,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-15151948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-15261443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-15284262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-15911865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-17881133,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-18440088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-19474385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-2702835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-9023841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19931137-9647613
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
pubmed-author:BlankStephanie VSV,
pubmed-author:CaputoThomas ATA,
pubmed-author:ChristosPaul JPJ,
pubmed-author:EinsteinMark HMH,
pubmed-author:GoldbergGary LGL,
pubmed-author:GoldmanNoahN,
pubmed-author:HershmanDawnD,
pubmed-author:IvyPercy SPS,
pubmed-author:KimMimiM,
pubmed-author:KuoDennis Yi-ShinDY,
pubmed-author:MuggiaFrancoF,
pubmed-author:PothuriBhavanaB,
pubmed-author:RunowiczCarolyn DCD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
442-6
|
|
pubmed:dateRevised |
2011-7-25
|
|
pubmed:meshHeading |
pubmed-meshheading:19931137-Adult,
pubmed-meshheading:19931137-Aged,
pubmed-meshheading:19931137-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19931137-Disease-Free Survival,
pubmed-meshheading:19931137-Female,
pubmed-meshheading:19931137-Humans,
pubmed-meshheading:19931137-Kaplan-Meier Estimate,
pubmed-meshheading:19931137-Middle Aged,
pubmed-meshheading:19931137-Neoplasm Metastasis,
pubmed-meshheading:19931137-Neoplasm Recurrence, Local,
pubmed-meshheading:19931137-Organoplatinum Compounds,
pubmed-meshheading:19931137-Paclitaxel,
pubmed-meshheading:19931137-Survival Rate,
pubmed-meshheading:19931137-Uterine Cervical Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
|
|
pubmed:affiliation |
Montefiore Medical Center/Albert Einstein College of Medicine, Suite 601, Bronx, NY 10461, USA. dykuo@montefiore.org
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
